Alzinova Investor Relations Material
Latest events
Study Result
Alzinova
Q1 2025
15 May, 2025
Q4 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Alzinova
Access all reports
Alzinova AB is a Swedish biotechnology company focused on developing treatments for Alzheimer's disease. The company's lead product is ALZ-101, a vaccine designed to target toxic oligomers of amyloid-beta, which are implicated in the progression of Alzheimer's. ALZ-101 has completed part A of its phase 1b clinical trial and continues to progress through clinical development. Alzinova is also working on ALZ-201, a monoclonal antibody that neutralizes these toxic oligomers, with a humanized version in early clinical trials. The company is headquartered in Mölndal, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
ALZ
Country
🇸🇪 Sweden